#dabrafenib

[pharmaceutical0]

Dabrafenib | CAS. No.1195765-45-7

Synonyms: Dabarefenib;GSK2118436;Tafinlar;Benzenesulfonamide,N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro

Chemical Name: N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethyl ethyl) -4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide

Know more:- https://www.simsonpharma.com/product/dabrafenib

[warningsine]

The NHS is to offer children with brain tumours in England a groundbreaking new targeted drug therapy to tackle the disease – a development charities are hailing as the biggest breakthrough in decades.

Gliomas are the most common type of brain cancer in children but experts say the standard treatment of chemotherapy can be brutal and gruelling, and also carries the risk of side-effects such as weight loss, seizures and headaches.

A kinder drug therapy has got the green light from the National Institute for Health and Care Excellence (Nice). Studies showed it caused fewer side-effects, improved children’s response rate to treatment and their survival time without the disease getting worse.

Dabrafenib with trametinib was found to halt the growth of tumours for more than three times as long as standard chemotherapy for children with low-grade gliomas that have a specific genetic mutation, while also helping spare many of the harsh side-effects of chemotherapy.

The treatment will initially be available on the NHS in England for people aged one to 17 with low- or high-grade gliomas that have a BRAF V600E mutation.

The combination treatment, which can be administered at home rather than in hospital, works by targeting the proteins made by the altered BRAF gene that are responsible for uncontrollable tumour growth.

Gliomas grow in the brain or spinal cord and can be low grade, where tumours grow slowly, or high grade, where they grow more rapidly and may be fatal. About 150 children are diagnosed with low-grade gliomas every year in the UK and about 30 are diagnosed with high-grade gliomas.

Clinical trials have shown that as well having fewer side-effects than chemotherapy, the treatment stalled growth of low-grade gliomas for about two years (24.9 months) on average – more than three times as long as standard chemotherapy (7.2 months), NHS England says.

In some cases, tumours disappeared, though longer-term follow-up of patients is needed.

Dabrafenib is given as dissolvable tablets that are taken twice a day, and trametinib is an oral solution taken once a day. The drugs work together by blocking the growth signal from the mutant BRAF protein and can slow or even stop the tumour from growing.

Dr Michele Afif, the chief executive of the Brain Tumour Charity, said: “We are delighted that Nice has approved the first new treatment for paediatric brain tumours in decades.

“Though this will only affect a small population, it is of huge significance to them and their loved ones and represents real progress. We hope that this will be the first of many new treatments that will ensure our community can live longer and better lives.”

Suki Sandhu, whose eight-year-old son Raj died from a high-grade glioma six years ago, welcomed the rollout of the new therapy on the NHS.

“I had to make the decision to stop chemotherapy treatment for my son as he was suffering with horrible side-effects after years of harsh treatment. It was one of the hardest decisions I have ever had to make … We need kinder drugs and new treatments for those with brain tumours, like this treatment, and I am hopeful other families will go on to get access to these drugs and, hopefully, remain disease-free for longer and live good quality lives.”

Prof Peter Johnson, the NHS England national clinical director for cancer, said: “It is a significant step forward in treatment that has been shown to be easier to take than chemotherapy and very effective in blocking the growth of the disease, helping children have a better quality of life for longer.

“It can also be taken at home, meaning children and teenagers can spend less time in hospital having treatment and more time with their loved ones and doing things they enjoy.”

[sunshinereisen]

Diagnose KREBS - Therapie-Bericht vom 20.11.2024 Dabrafenib (Tafinlar®) + Trametinib (Mekinist®) Eine zielgerichtete Therapie für fortgeschrittenes Melanom blockiert die Aktivität bestimmter Moleküle in Krebszellen, die das Zellwachstum steuern. Zwei dieser Medikamente, Dabrafenib (Tafinlar) und Trametinib (Mekinist), lassen Tumore schrumpfen und helfen Patienten mit fortgeschrittenem Melanom, länger zu leben.

[cancer-specialist-in-pune]

Targeted Therapy and Immunotherapy for Gallbladder Cancer

As researchers learn more about the changes in cells that cause gallbladder cancer, they’ve developed drugs to target some of these changes. These targeted drugs work differently from standard chemotherapy (chemo) drugs. They sometimes work when standard chemo drugs don’t, and they often have different side effects.

FGFR2 inhibitors:

FGFRs (fibroblast growth factor receptors) are proteins on cells that help them grow and divide normally. A small number of people with gallbladder cancer have changes in the genes that make FGFRs, which result in abnormal FGFR proteins that cause cells to grow out of control and turn into cancer.

Pemigatinib (Pemazyre) and futibatinib (Lytgobi) are FGFR2 inhibitors. They block the abnormal FGFR2 protein in gallbladder cancer cells and keep them from growing and spreading to other places.

These drugs can be used to treat some advanced gallbladder cancers that cannot be removed by surgery or have spread to distant areas after at least one previous chemotherapy treatment. For these drugs to work, your cancer must have an abnormal FGFR2 gene, so your cancer will be tested before starting any of these drugs.

These medicines are taken by mouth as tablets, typically once a day.

IDH1 inhibitor:

In some people with gallbladder cancer, the cancer cells have a change (mutation) in the IDH1 gene, which normally helps cells make the IDH1 protein. Mutations in this gene can lead to an abnormal IDH1 protein, which can stop cells from maturing the way they normally would.

Ivosidenib (Tibsovo) is an IDH1 inhibitor. It blocks the abnormal IDH1 protein, which seems to help the cancer cells mature into more normal cells. This drug can be used in people with advanced, previously treated gallbladder cancer, if the cancer cells are found to have an IDH1 mutation. Your doctor can test your cancer cells to see if they have an IDH1 mutation.

This drug is taken by mouth, once a day.

Less common but more serious side effects can include changes in heart rhythm, pneumonia, and jaundice (yellowing of the eyes and skin).

NTRK inhibitor:

A very small number of gallbladder cancers have changes in one of the NTRK genes, called NTRK gene fusions. Cells with these gene changes make abnormal TRK proteins, which can lead to abnormal cell growth and cancer.

Larotrectinib (Vitrakyi) or entrectinib (Rozlytrek) are NTRK inhibitors. TRK inhibitors target and disable the proteins made by the NTRK genes. This drug can be used in people with advanced gallbladder cancer, who have not received prior systemic therapy.

These drugs are taken as pills, once or twice daily.

Possible side effects of NTRK inhibitors:

Common side effects can include abnormal liver tests; decreased white blood cell and red blood cells; muscle and joint pain; tiredness; diarrhea or constipation; nausea and vomiting; and stomach pain.

Less common but more serious side effects can include mental changes, such as confusion, changes in mood, changes in sleep; liver damage; changes in heart rhythm and/or function; vision changes; harm to a fetus.

BRAF inhibitor:

In some gallbladder cancers, the cells have changes in the BRAF gene. Cells with these changes make an altered BRAF protein that helps them grow. Some drugs target this and related proteins. A combination of BRAF inhibitor and a MEK inhibitor is often given together to treat advanced cancer with the BRAF V600E mutation.

Dabrafenib (Tafinlar) is a BRAF inhibitor. Trametinib (Mekinist) is a MEK inhibitor. This drug combination can be used in people with advanced, previously treated gallbladder cancer, if the cancer cells are found to have an BRAF V600E mutation.

These drugs are taken as pills or capsules each day.

Possible side effects of BRAF inhibitor:

Common side effects can include skin thickening, rash, itching, sensitivity to the sun, headache, fever, joint pain, tiredness, hair loss, nausea, and diarrhea.

Less common but more serious side effects can include bleeding, heart rhythm problems, liver or kidney problems, lung problems, severe allergic reactions, severe skin or eye problems, increased blood sugar levels, and squamous cell skin cancer.

RET inhibitor:

In a small percentage of gallbladder cancers, the tumor cells have a rearrangement in the RET gene that causes them to make an abnormal form of the RET protein. This abnormal protein helps the tumor cells grow. 

Selpercatinib (Retevmo) or pralsetinib (Gayreto) are RET inhibitors and can be used to treat advanced gallbladder cancers with the RET rearrangement.

These drugs are taken by mouth as capsules, typically once or twice a day.

Possible side effects of RET inhibitors:

Common side effects can include dry mouth, diarrhea or constipation, high blood pressure, tiredness, swelling in hands and/or feet, skin rash, muscle and joint pain, low blood cell counts, or changes in other blood tests.

Less common but more serious side effects can include liver damage, lung damage, allergic reactions, changes in heart rhythm, bleeding easily, and problems with wound healing.

KRAS inhibitor:

In some gallbladder cancers, the cancer cells have changes in the KRAS gene called a KRAS G12C mutation.  This mutation makes an abnormal form of the KRAS protein, which helps the cancer cells grow and spread.  KRAS inhibitors attach to the KRAS G12C protein, which helps keep cancer cells from growing.

Adagrasib (Krazati) is a KRAS inhibitor and is used to treat advanced gallbladder cancer with the KRAS G12C mutation if you’ve already had at least one other type of drug treatment.

This drug is taken as a pill, typically twice a day.

Possible side effects of KRAS inhibitor:

Common side effects can include diarrhea, nausea and vomiting, muscle pain, fatigue, cough, decreased white blood cell and red blood cell counts, and changes in other blood tests.

If you need targeted therapy and immunotherapy for gallbladder cancer, please book an appointment with our cancer specialist in Pune, Dr. Pratik Patil.

[ptmasterguide]

Adragasib: A Targeted Therapy for BRAF-Mutated Melanoma

Adragasib: A Targeted Therapy for BRAF-Mutated Melanoma Adragasib (also known as dabrafenib) is a targeted therapy medication used primarily to treat metastatic melanoma, a type of skin cancer. It works by inhibiting the growth of cancer cells that have a specific mutation in the BRAF gene. Uses of Adragasib: Metastatic Melanoma: Adragasib is approved to treat patients with advanced or…

[creativeera]

Metastatic Melanoma Therapeutics: New Breakthroughs in Cancer Treatment and Management

Metastatic melanoma, also known as advanced or stage IV melanoma, occurs when melanoma cells spread from the primary skin cancer site to other organs in the body. When melanoma reaches this advanced stage, it becomes much more difficult to treat and can be life-threatening if left untreated. In this article, we will explore the current treatment landscape for metastatic melanoma and recent therapeutic advances that are improving outcomes for patients. Standard Metastatic Melanoma Therapeutics

For many years, chemotherapy was one of the only systemic treatment options available for metastatic melanoma. Chemotherapies like dacarbazine (DTIC) were sometimes used but provided limited benefits, with overall response rates of only 10-15% and median survival times of 6-9 months. Combination chemotherapy regimens like carboplatin plus paclitaxel were also tested but did little to improve on the poor outcomes seen with single-agent DTIC. Toxicities were also a major issue, as chemotherapy for melanoma is associated with significant side effects. The lack of effective chemotherapy options highlighted the urgent need for new targeted and immunotherapeutic treatments. Advances in Targeted Therapies

In recent years, major breakthroughs have been made with targeted therapies that inhibit specific molecular alterations driving Metastatic Melanoma Therapeutics growth and progression. BRAF inhibitors like vemurafenib and dabrafenib were some of the first targeted drugs approved for metastatic melanoma. These work by blocking a mutated version of the BRAF protein found in around 50% of advanced melanomas. While initial responses can be dramatic, resistance often develops within 6-7 months on average. Newer combinations of BRAF and MEK inhibitors like vemurafenib plus cobimetinib or dabrafenib plus trametinib have helped extend responses and improve outcomes compared to BRAF inhibitors alone. Combination targeted therapy is now considered the standard of care for BRAF-mutant metastatic melanoma. Efforts to overcome resistance through additional pathways are also underway. The Immunotherapy Revolution

The biggest breakthrough has been with immunotherapies that unlock the body's own immune defenses. In 2011, the CTLA-4 inhibitor ipilimumab became the first drug shown to improve overall survival in metastatic melanoma compared to chemotherapy. While only benefiting a minority of patients, this marked a seminal moment as it proved the concept of immunotherapy for advanced disease. Since then, PD-1 inhibitors such as pembrolizumab and nivolumab have revolutionized treatment. These works by releasing brakes on T cells allowing the immune system to better recognize and destroy melanoma cells. Response rates of 40-50% are now achievable depending on the drug and biomarkers, with some patients experiencing durable remissions lasting many years. Combination immunotherapies are also demonstrating even higher response rates. Immunotherapies have now become the standard of first-line treatment for most patients with metastatic melanoma, regardless of BRAF mutation status. Managing Immunotherapy Toxicities

While tremendously effective at eliciting tumor control, immunotherapies can also cause unique immune-related side effects, known as immune-related adverse events (IRAEs). These result from over-activation of the immune system against normal tissues. Common IRAEs include fatigue, rash, diarrhea, colitis, hepatitis, hypophysitis, and pneumonitis. Most side effects are manageable with immunosuppressive corticosteroids but can sometimes be severe or life-threatening. Careful monitoring during and after treatment is important, along with patient education on recognizing symptoms that require prompt evaluation. Steroid-refractory IRAEs may necessitate additional immunosuppressive agents like infliximab or mycophenolate mofetil. Managing toxicities properly is crucial for maintaining patient safety and tolerability of highly effective immunotherapies. Ongoing Clinical Trials

Researchers continue pushing the boundaries to improve outcomes even further. Numerous clinical trials are exploring combination strategies pairing immunotherapies with targeted therapies, chemotherapy, radiotherapy or other immunotherapies. Biomarkers to predict response are also an active area. Other investigations focus on optimizing dosing and sequences. Adjuvant therapy studies seek to prevent recurrence after surgery. Cell therapies using TILs (tumor-infiltrating lymphocytes) are showing promise and may benefit non-responders. Efforts are also underway to overcome immunotherapy resistance. With rapid ongoing advances, the future looks bright for developing even more effective precision options tailored to individual tumor and patient factors. metastatic melanoma was once a dismal diagnosis with very limited treatment options and poor survival. Remarkable progress over the last decade has completely transformed the treatment paradigm. Approval of targeted therapies and immunotherapies has produced much higher response rates and longer life expectancies than ever seen before. While challenges remain in fully overcoming resistance and maximizing benefit for every patient, the immunology revolution has established immunotherapy as a mainstay for melanoma. Continued research advances will help usher in an even brighter future, offering new hope to those diagnosed with this deadly disease.

Get more insights on Metastatic Melanoma Therapeutics

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

[drsayyed]

Comprehensive Guide to Cancer Skin Treatment: Options and Considerations

Skin cancer is one of the most common types of cancer worldwide, but with early detection and effective treatment, it is often highly treatable. Understanding the various options for skin cancer treatment is crucial for patients and their loved ones. This article provides an overview of the most common types of skin cancer treatments, helping you make informed decisions about your care.

Types of Skin Cancer

Before exploring treatment options, it’s important to understand the main types of skin cancer:

Basal Cell Carcinoma (BCC): The most common and least aggressive type of skin cancer. It often appears as a small, shiny bump or nodule on the skin, particularly in areas exposed to the sun.

Squamous Cell Carcinoma (SCC): This type is more aggressive than BCC and can spread to other parts of the body. It usually appears as a red, scaly, or crusted lesion.

Melanoma: The most dangerous form of skin cancer, melanoma can spread rapidly to other parts of the body. It often appears as a mole that changes shape, size, or color. Cancer Skin Treatment

Treatment Options

Surgical Options

Excisional Surgery: This is the most common treatment for skin cancer. The surgeon removes the cancerous tissue along with some surrounding healthy skin to ensure all cancer cells are eliminated.

Mohs Surgery: Particularly effective for BCC and SCC, Mohs surgery involves removing thin layers of skin one at a time and examining them under a microscope until no cancer cells are detected. This method preserves as much healthy tissue as possible.

Curettage and Electrodessication: Used primarily for small BCCs and SCCs, this technique involves scraping away the cancerous tissue and using electric currents to destroy any remaining cells.

Non-Surgical Options

Radiation Therapy: High-energy rays are used to target and kill cancer cells. This is often used for patients who cannot undergo surgery or when the cancer is in a location that is difficult to operate on.

Cryotherapy: This treatment involves freezing cancerous tissue with liquid nitrogen, which then falls off as the skin heals. It is typically used for precancerous conditions and small skin cancers.

Topical Treatments: Certain creams and ointments can be applied directly to the skin to treat superficial BCC and SCC. These medications, such as 5-fluorouracil (5-FU) and imiquimod, help destroy cancerous cells.

Photodynamic Therapy (PDT): This involves applying a light-sensitive drug to the skin and then exposing it to a special light that activates the drug, killing the cancer cells.

Advanced Treatments

Immunotherapy: For advanced melanoma, immunotherapy can help boost the body’s immune system to fight cancer. Drugs like pembrolizumab and nivolumab have shown promising results.

Targeted Therapy: This treatment uses drugs to target specific genes or proteins that are involved in the growth and survival of cancer cells. For melanoma, drugs like vemurafenib and dabrafenib can be effective.

Considerations and Follow-Up

Selecting the appropriate treatment depends on various factors, including the type, size, location, and stage of the cancer, as well as the patient’s overall health and preferences. Early detection is critical, so regular skin checks and prompt attention to new or changing skin lesions are essential.

After treatment, follow-up care is crucial to monitor for recurrence and manage any side effects. Patients should maintain regular check-ups with their dermatologist and adopt protective measures against UV exposure, such as using sunscreen and wearing protective clothing.

Conclusion

Skin cancer treatment has advanced significantly, offering multiple effective options tailored to individual needs. By understanding these treatments and maintaining vigilant skin care, patients can manage their condition and improve their prognosis. If you suspect any changes in your skin, consult a healthcare professional promptly to ensure the best possible outcomes.

For more info visit here:- Treatment For Depression Near Me

[gauricmi]

The Growing Landscape of the Cancer Immunotherapy Market

A) Market Overview: The global Cancer Immunotherapy Market is estimated to be valued at US$ 93,407.0 million in 2021 and is projected to reach US$ (market value for 2022) million by 2022, exhibiting a CAGR of (given CAGR) % over the forecast period. Cancer immunotherapy involves the use of the body's immune system to fight against cancer cells. This revolutionary approach has gained significant attention and traction in recent years due to its potential to provide a more effective and targeted treatment option for various types of cancers. B) Market Key Trends: With the rapid advancements in medical research and technology, the cancer immunotherapy market is witnessing several key trends. One major trend is the increasing adoption of combination therapies. Researchers and pharmaceutical companies are exploring the synergistic effects of combining different immunotherapies with traditional treatments like chemotherapy and radiation therapy. This approach aims to enhance the overall efficacy of the treatment and improve patient outcomes. For example, the combination of immune checkpoint inhibitors with targeted therapies has shown promising results in certain types of cancer, such as melanoma. The combination of pembrolizumab (Keytruda) and targeted therapy dabrafenib plus trametinib has demonstrated superior progression-free survival rates compared to monotherapy in patients with advanced melanoma. C) Porter's Analysis: Threat of new entrants: The Cancer Immunotherapy Market Growth is highly competitive and characterized by a significant level of research and development investments. The high cost of drug development, regulatory requirements, and complex manufacturing processes act as barriers to entry for new players. Bargaining power of buyers: Due to the vital nature of cancer treatments, buyers (such as healthcare institutions and patients) have limited bargaining power. The demand for effective and safe cancer immunotherapies outweighs the influence of buyers to negotiate lower prices. Bargaining power of suppliers: Suppliers in the cancer immunotherapy market, including pharmaceutical companies and contract manufacturing organizations, hold a stronger bargaining power. They possess the expertise and resources required for drug development, production, and distribution. Threat of new substitutes: While traditional treatments like chemotherapy and radiation therapy remain prevalent, the advent of cancer immunotherapy has provided an innovative and promising alternative. The development of effective immunotherapies reduces the threat of substitutes for cancer treatments. Competitive rivalry: The cancer immunotherapy market is highly competitive, with several key players vying for market share. Novartis AG, Merck & Co. Inc., F-Hoffmann La Roche, Eli Lilly and Company, Bayer AG, AstraZeneca, Astellas Pharma Inc., Amgen Inc., OSE Immunotherapeutics SA, and Bristol-Myers Squibb Company are among the leading companies operating in this space. These players invest extensively in research and development to innovate new therapies and gain a competitive edge. D) Key Takeaways: The global cancer immunotherapy market is expected to witness high growth, exhibiting a CAGR of (given CAGR) over the forecast period, driven by the increasing prevalence of cancer and the growing demand for effective and targeted treatment options. The rise in investments in research and development activities, as well as the collaboration between pharmaceutical companies and research institutes, are also contributing factors. Regionally, (mention the fastest-growing and dominating region) is projected to dominate the cancer immunotherapy market due to its well-established healthcare infrastructure, favorable reimbursement policies, and a high prevalence of cancer cases. Additionally, the increasing focus of key players on expanding their presence in emerging markets, such as (mention specific emerging markets), is expected to further fuel the market growth.

[delvenservices]

Thyroid Cancer Drug Market Size to Reach at a Highest CAGR of 21.48% by 2028

Thyroid Cancer Drug Market, By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC) and Anaplastic Thyroid Cancer), Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy, and Surgery), Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, and Others), Route of Administration (Oral, Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America)

The global Thyroid Cancer Drug market is anticipated to reach USD 3.54 billion in 2021 growing at a CAGR of 21.48% during the forecasting period, 2021-2028.

Thyroid cancer is the cancer of the thyroid gland which is located in the neck region of the human body. It is a butterfly-shaped gland that releases 3 hormones 1.triidothyronine (T3) 2.thyroxin (T4) 3.Calcitonin. The thyroid gland uses iodine from the blood to make these hormones and stores and releases the hormones when required. Proper functioning of the thyroid gland is essential for the normal metabolism of the body.

A recent increase in the cases of thyroid cancer and unhealthy lifestyle contributing to the disease prevalence along with the RD in the sector are some of the factors that have supported long-term expansion for the Thyroid Cancer Drug industry.

Get the Free Sample Copy: https://www.delvens.com/get-free-sample/thyroid-cancer-drug-market-trends-forecast-till-2028

Key Findings

The global Thyroid Cancer Drug market is segmented into Type, Treatment, Drug Type, Route of Administration, End-Users, and geography.

The type segment is segmented into Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC), and Anaplastic Thyroid Cancernal Fixators, Braces, and Prosthesis

Treatment segment is segmented into Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy, and Surgery

The end-User segment is segmented into Hospitals, Homecare, Specialty Clinics, Others

The drug type segment is segmented into Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, and Others

Route of administration segment is segmented into Oral, Injectable, and Others

Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/thyroid-cancer-drug-market-trends-forecast-till-2028

Regional Analysis:

Geographically, the global Thyroid Cancer Drug market is sub-segmented into North America, Europe, Asia-Pacific, Middle East, and Africa and South America, and insights are provided for each region and major countries within the regions

Competitive Landscape

Key players in the global Thyroid Cancer Drug market are Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc., and Vascular Biogenics among others.

Purchase the Report at: https://www.delvens.com/checkout/thyroid-cancer-drug-market-trends-forecast-till-2028

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors

Gain authentic and granular data access for the Thyroid Cancer Drug market to understand the trends and the factors involved in changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Read Related Reports:

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[mrunalnerkarblog]

Increasing FDA approval for thyroid cancer drug is expected to present profitable market opportunities

Thyroid disorder therapy is a fast-growing area of treatment for people suffering from this condition. The thyroid gland is responsible for regulating metabolism and temperature, with control through the use of the thyroid gland located in the neck just below the voice box. A person suffering from Thyroid disorder have signs and symptoms such as weight gain, fatigue, depression, and constipation. Thyroid Dysfunction may be caused by many factors, and the causes and symptoms are different in every person. Thyroid disease is a highly treatable condition if diagnosed early enough, although treatment options will vary from person to person depending on their age, overall health, and underlying health problems.

The growing prevalence of thyroid disorder around the globe is a prime factor driving the market growth of thyroid disorder therapy. According to the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease. Up to 60 percent of those with thyroid disease are unaware of their condition. Women are five to eight times more likely than men to have thyroid problems. The increasing geriatric population coupled with the rise in the global healthcare expenditure is again expected to augment the market growth of thyroid disorder therapy.

North America is expected to gain significant growth over the forecast period and this is attributed to the increasing prevalence of thyroid cancer coupled with the continuous FDA approval for the new and advanced drug. For instance, in December 2020, the Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for RET-altered thyroid cancers. Moreover, increasing spending by the government on cancer treatment for improving patient care is further anticipated to augment the regional market growth of thyroid disorder therapy over the forecast period.

Key Developments:

1.      In October 2020, BDR Pharmaceutical announced the launch of 4 mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver cancer, and advanced kidney cancer.

2.      In July 2020, Roche and its Genentech subsidiary announced its partnership with Blueprint Medicines to develop and commercialize the once-daily oral cancer drug pralsetinib in most of the world.

3.      In May 2018, FDA has approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.

[namedpatientprogram]

What is the mechanism of action of Dabrafenib, and how does it specifically target cancer cells?

Dabrafenib, marketed under the brand name Tafinlar, is a prescription medication used to treat certain types of cancers. Specifically, dabrafenib is indicated for the treatment of melanoma with BRAF V600E or V600K mutations, as well as non-small cell lung cancer with BRAF V600E mutations. Dabrafenib belongs to a class of medications known as BRAF inhibitors, which work by targeting a specific genetic mutation found in some cancer cells.

[ptmasterguide]

Tafinlar (Geriatric Use)

Tafinlar (Geriatric Use) Tafinlar (dabrafenib) is a medication primarily used in the treatment of certain types of skin cancer, specifically melanoma with a specific genetic mutation. While Tafinlar is not specifically indicated for geriatric use, it may be prescribed to older adults if they meet the criteria for its use and can tolerate the medication.